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The complement system is a key component of the host immune response for the recognition and clearance of Streptococcus
pneumoniae. In this study, we demonstrate that the amidase LytA, the main pneumococcal autolysin, inhibits complement-me-
diated immunity independently of effects on pneumolysin by a complex process of impaired complement activation, increased
binding of complement regulators, and direct degradation of complement C3. The use of human sera depleted of either C1q or
factor B confirmed that LytA prevented activation of both the classical and alternative pathways, whereas pneumolysin inhibited
only the classical pathway. LytA prevented binding of C1q and the acute-phase protein C-reactive protein to S. pneumoniae,
thereby reducing activation of the classical pathway on the bacterial surface. In addition, LytA increased recruitment of the com-
plement downregulators C4BP and factor H to the pneumococcal cell wall and directly cleaved C3b and iC3b to generate degra-
dation products. As a consequence, C3b deposition and phagocytosis increased in the absence of LytA and were markedly en-
hanced for the lytA ply double mutant, confirming that a combination of LytA and Ply is essential for the establishment of
pneumococcal pneumonia and sepsis in a murine model of infection. These data demonstrate that LytA has pleiotropic effects on
complement activation, a finding which, in combination with the effects of pneumolysin on complement to assist with pneumo-
coccal complement evasion, confirms a major role of both proteins for the full virulence of the microorganism during
septicemia.
Streptococcus pneumoniae (also termed the pneumococcus) col-onizes the human nasopharynx in a high percentage of the
population and can be carried asymptomatically from the first
days of life (1). S. pneumoniae is themost common etiologic agent
of acute otitis media and community-acquired pneumonia and a
major cause of bacterial sepsis and meningitis, resulting in signif-
icant rates of morbidity and mortality worldwide (2). Prevention
of pneumococcal disease requires efficient recognition and clear-
ance of the invading pathogen by the complement system and
professional phagocytes (3, 4). Activation of the three comple-
ment cascades—termed the classical pathway (CP), the alternative
pathway (AP), and the lectin pathway—leads to the formation of
the key complement component C3b, which plays a pivotal role in
the host immune response, such as opsonization and clearance of
invading pathogens (5–7). The CP is important for complement
recognition of pneumococci and is generally activated by the rec-
ognition of antigen-antibody complexes on the bacterial surface
(6, 8) as part of the adaptive immune response and by natural IgM,
the lectin SIGN-R1, and acute-phase proteins as part of the innate
immune response (6, 9, 10). In addition, the AP is activated by the
spontaneous hydrolysis of the C3 component, triggering the am-
plification of C3 deposition (11, 12), and mannose binding lectin
pathway activation has also recently been reported for S. pneu-
moniae (7). A finely controlled set of specific surface-bound and
fluid-phase regulators, such as C4b-binding protein (C4BP) and
factor H (FH), protects host cells from complement activation
and complement-mediated damage (13–18).
Although the expression of the S. pneumoniae capsule is essen-
tial for the virulence of the microorganism, numerous pneumo-
coccal proteins also contribute to pathogenesis, including by
promoting complement evasion (3, 19). For example, the S. pneu-
moniae cell wall protein PspC can recruit the complement down-
regulators C4BP and FH to the bacterial cell surface, thereby in-
hibiting activation of the CP and AP, respectively (13–18). In
addition, the cholesterol-dependent cytolysin pneumolysin (Ply)
(20) prevents CP-mediated complement recognition of pneumo-
cocci through interactions with the CP component C1q (3, 21).
However, export of Ply into extracellular fluid or for attachment
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to the cell wall seems to require lysis of the bacteria (22). The
pneumococcal protein involved in lysis is the major autolytic en-
zyme of the bacterium and is termed LytA, an amidase that cleaves
the N-acetylmuramoyl-L-alanine bonds of pneumococcal pepti-
doglycan (23). Previously, LytA was thought to contribute toward
pneumococcal pathogenesis due to its importance for the release
of Ply and inflammatory mediators, such as teichoic acids and
peptidoglycan fragments from S. pneumoniae (23, 24), rather than
direct effects on immune evasion independent of Ply.
In this study, we have investigated the contribution of Ply and
LytA to the establishment of invasive pneumococcal disease
(IPD), exploring their role in essential aspects of the pathogenesis
process, including evasion of different components of the host
immune response.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The S. pneumoniae clinical iso-
lates used were D39 (NCTC 07466, serotype 2 [ST2]); strain S3 lytA
(ST23F) and its complemented mutant, S3C (lytA) (25); and strain
1515/97 (ST6B) and its lytA-deficient strain (26). Isogenic D39 mutants
withmutations in lytA, ply, pspC, or lytBwere constructed by transforma-
tion, using standard protocols (18, 21, 27, 28), with DNA prepared from
mutants previously characterized. Pneumococcal strains expressing the
green fluorescent protein (GFP) were constructed by genetic transforma-
tion with pMV158GFP (tetracycline resistant) as previously described
(28). Kanamycin (250g/ml), erythromycin (0.2g/ml), and tetracycline
(0.5 g/ml) were added to blood agar plates for isolation of bacterial
transformants. S. pneumoniae strains were cultured on blood agar plates
at 37°C in aCO2 atmosphere or in Todd-Hewitt broth supplementedwith
0.5% yeast extract to an optical density at 550 nm (OD550) of 0.5 and
stored at70°C in 10% glycerol as single-use aliquots.
Binding of complement factors to S. pneumoniae. A pool of sera
from five healthy male volunteers unvaccinated against S. pneumoniae
(median age, 40 years) was obtained with informed consent according to
institutional guidelines (LIB 14/2007, 3 July) and stored as single-use ali-
quots at70°C as a source of complement and serum components. C1q,
C3b, FH, C4BP, and C-reactive protein (CRP) were assessed using flow
cytometry assays as previously described (10, 18, 28). Human sera de-
pleted of C1q and factor B were purchased from Calbiochem. C3b depo-
sition was detected by incubating 5 106 CFU of the bacteria opsonized
with 20% serum using a fluorescein isothiocyanate (FITC)-conjugated
polyclonal goat anti-human C3b antibody (ICN-Cappel) diluted 1/300 in
phosphate-buffered saline (PBS)–0.1% Tween 20. After incubation, the
bacteria were washed with PBS–Tween 20 (0.02%) to remove unbound
components, fixed in 3% paraformaldehyde, and analyzed on a FAC-
SCalibur flow cytometer (BD Biosciences) or a Beckman Coulter Cytom-
ics FC500 flow cytometer using forward and side scatter parameters to
gate on at least 25,000 bacteria. The results were expressed as a relative
percent fluorescence index (FI) that measures not only the proportion of
fluorescent bacteria positive for the host serum component investigated
but also the intensity of fluorescence, which quantifies the immune com-
ponent bound (8). This assay was adapted to assess the binding to C1q,
CRP, FH, andC4BP using a conjugated polyclonal sheep anti-humanC1q
antibody (Serotec), a polyclonal rabbit anti-human CRP antibody (Cal-
biochem), a polyclonal sheep anti-human FH antibody (Serotec), and a
polyclonal sheep anti-human C4BP antibody (Serotec). To detect CRP,
FH, and C4BP, secondary staining in PBS–0.1% Tween 20 containing
FITC-conjugated polyclonal goat anti-rabbit or FITC/DyLight 649 anti-
sheep antibodies (Serotec) was performed. A direct interaction between
purified LytA and purifiedC4BP or FHwas determined by enzyme-linked
immunosorbent assay (ELISA) as previously described (10). Briefly,Nunc
MaxiSorp 96-well plates were coated with 10g/ml of purified LytA for 2
h at 37°C and blocked with a PBS–2% bovine serum albumin (BSA) so-
lution before 50l of different concentrations of purified humanC4BP or
FHwas added to each well. After 2 h of incubation at 37°C, the plates were
incubated with 50 l of sheep anti-human C4BP or FH (Serotec) diluted
1/2,000 in PBS. Finally, the plates were incubated with 50 l of rabbit
antisheep HRP antibody (Santa Cruz) for 30 min and developed using
o-phenylenediamine (Sigma-Aldrich) before determining the OD492 us-
ing a microtiter plate reader (Anthos 2020).
Quantification of Pcho and PspC. The level of phosphorylcholine
(Pcho) and PspC on the bacterial surface was detected by flow cytometry
as previously described (28). The conditions of the assays were the same as
those described above for complement components, except that the bac-
terial strains were incubated for 1 h at 37°C with TEPC-15 antibody (a
monoclonal antibody specific for Pcho [Sigma-Aldrich]) diluted 1/25 or
rabbit polyclonal antibody to PspC (a kind gift from Sven Hammer-
schmidt, University of Greifswald, Greifswald, Germany) diluted 1/300.
The secondary antibodies used for the detection of Pcho and PspC were
rabbit antimouse FITC (Serotec) and goat antirabbit FITC (Serotec), re-
spectively.
C3b/iC3b degradation by LytA. Purified LytA (displaying amidase
activity), the carboxy-terminalmoiety or choline-binding domain of LytA
(C-LytA), and the enzymatically inactive LytAH133A protein (a mutated
LytA amidase containing a His133 ¡ Ala substitution [LytAH133A] that
inactivates the enzyme [29]) were obtained by overexpression of previ-
ously described plasmids in Escherichia coli (30). A lytA-deficient strain
was opsonized for 20 min with human serum, and after two washes with
PBS–Tween 20, proteins were added and the C3b level was explored by
flow cytometry. To detect C3 fragments by Western blotting, a lytA-null
strain was opsonized with 50% human serum as a source of C3b in the
absence or in the presence of different pneumococcal proteins (LytA,
C-LytA, LytAH133A, or the LytC lysozyme) for 2 h at 37°C. A sample of
each supernatant was analyzed by 15% sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE), the proteins were transferred to a
membrane, and fragments were revealed by immunoblotting using a goat
anti-human C3b antibody. As controls, purified C3b proteins treated and
not treatedwith FH and factor I were included. Additionally, purifiedC3b
and iC3b proteins (3 g) in sodium phosphate buffer (20 mM, pH 6.9)
were treated with 3 ng of LytA or LytAH133A and incubated for 2 h at 37°C.
Samples were analyzed by SDS-PAGE using Tricine instead of Tris-gly-
cine (31, 32).
Interaction of S. pneumoniaewith phagocytes. Experiments investi-
gating the recognition and phagocytosis by alveolar macrophages (AMs)
were performed as previously described (27, 33). Briefly, murine MH-S
cells (CRL-2019; American Type Culture Collection [ATCC]) were used
as AMs and were grown in RPMI tissue culture medium supplemented
with 10% heat-inactivated fetal calf serum and HEPES (10 mM). To test
the recognition of the wild type and the different mutants by AMs, cells
(seeded in 24-well plates containing 7 105 cells perwell) were infected in
triplicate with 50l of a suspension of the pneumococcal strains at a ratio
of 50 bacteria to 1 cell and incubated at 37°C. For adhesion assays, cells
were infected for 1 h, washed five times with PBS, and lysed with 300l of
a solution containing 0.025% saponin-PBS for 10 min. For phagocytosis
assays, cells that had previously been infected for 1 h were washed five
times with PBS and incubated for an additional hour in tissue culture
medium containing penicillin (10g/ml) and gentamicin (200g/ml) to
kill extracellular bacteria. Viable bacteria recovered from infected cells
were obtained by plating serial dilutions on blood agar plates.
Phagocytosis by neutrophils was evaluated using HL-60 cells (CCL-
240; ATCC) differentiated to granulocytes, and the general conditions of
the assay were based on those described previously (10, 27, 34). Briefly, S.
pneumoniae strains were fluorescently labeled by incubation with 6-car-
boxyfluorescein, succinimidyl ester (FAM-SE; Molecular Probes), solu-
tion (10 mg/ml in dimethyl sulfoxide; Sigma-Aldrich) in 0.1 M sodium
bicarbonate buffer for 1 h at 37°C and then washed six times with Hanks
balanced salt solution (HBSS)–0.2%BSA and stored in aliquots at70°C
in 10% glycerol for further assays. Infection assays were performed with
bacteria at a ratio of 10 bacteria per cell. A minimum of 6,000 cells were
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analyzed using a Cytomics flow cytometer. Results were expressed as a
relative percent phagocytosis index, defined as the proportion of cells
positive for fluorescent bacteria multiplied by the geometric mean of the
fluorescence intensity, which correlates with the amount of bacteria
phagocytosed per cell (8, 10, 27).
Confocalmicroscopy. S. pneumoniae strains expressingGFPwere ob-
tained by transformation with pMV158GFP and were used for immuno-
fluorescence microscopy. MH-S cells and HL-60 cells that had previously
been infected as described above were seeded on 12-mm circular cover-
slips for immunofluorescence staining. As theHL-60 cells were in suspen-
sion, the cells were centrifuged at 70  g for 2 min using a Cytospin
centrifuge (Thermo Electron, Pittsburgh, PA). For the detection of late
endosomal markers in AMs, we stained late antigen membrane protein 1
(LAMP1) or LAMP2.Coverslips containing the infected cells werewashed
twice in PBS containing 0.1% saponin and once in PBS and incubated for
30 min with primary antibodies. Staining was performed in PBS contain-
ing 10% horse serum, 0.1% saponin, and the primary antibodies using rat
anti-mouse LAMP1 or LAMP2 (Southern Biotech) diluted 1/200, and the
DNAwas stained withHoechst (Invitrogen) diluted 1/2,500. After 30min
incubation with primary antibodies at room temperature, the coverslips
were washed twice with PBS–0.1% saponin and once with PBS (pH 7.0)
before incubation for 30min at room temperaturewith a 1/200 dilution of
the secondary antibody goat antirat tetramethylrhodamine isocyanate
(Serotec). The actin cytoskeleton was stained with rhodamine-phalloidin
(Invitrogen) diluted 1:200. Finally, the coverslips were washed twice in
PBS containing 0.1% saponin, once in PBS, and once in H2O; mounted
with Aqua Poly/Mount (Polysciences); and analyzed with a Leica spec-
tral SP5 confocal microscope using Leica software (LAS-AF).
Experimental models of infection. C57BL/6 mice were bred by the
CIB-CSIC and ISCIII animal facilities. All mice used were 8 to 16 weeks
old, andwithin each experiment, groups ofmicewerematched for age and
sex. In studies investigating the role of Ply and LytA in the establishment
of pneumococcal sepsis and pneumonia, groups of 5 mice each were in-
fected as previously described (10). Briefly, for the sepsis model of infec-
tion, mice were challenged with 1  106 CFU/ml of each strain (in a
volume of 200 l) by the intraperitoneal route, whereas for pneumonia,
mice, which were under anesthesia with isoflurane, were inoculated intra-
nasally with 50 l containing 107 CFU/mouse. At 24 h after challenge, a
lethal dose of pentobarbital was administered and bacterial counts were
determined from samples recovered from bronchoalveolar lavage (BAL)
fluid, lung, and blood. Experiments were repeated twice using 5 mice in
each group, and results are expressed as the log number of CFU of bacte-
ria/ml recovered from the different sites. All animal procedures were ap-
proved by the Animal Care and Use Committees of CIB-CSIC and ISCIII
(approval reference numbers CIB-FJD 06010017 andCBBA-PA 52_2011-
v2, respectively).
Quantification of capsular polysaccharide. Serotype 2 pneumococ-
cal capsular polysaccharide (CPS) was either purchased from ATCC or
prepared as previously described (35). Glucuronic acid was determined
with m-hydroxydiphenyl, as previously described (36), using type 2 CPS
as a standard and measuring the OD520 using a microtiter plate reader
(Anthos 2020). Recognition of the CPS of serotype 2 strains by specific
antibodies was studied by the flow cytometry assay explained above using
thewild-typeD39 strain and the isogenic lytAmutant strain. The antibod-
ies used for detection were rabbit anti-serotype 2 (Statens Serum Institut)
diluted 1/200 and a secondary goat antirabbit FITC-conjugated antibody
(Santa Cruz) diluted 1/300. Results are expressed as a fluorescence index,
as explained above.
Statistical analysis. Data are representative of the results obtained
from repeated independent experiments, and each point represents the
mean and standard deviation (SD) from 3 to 5 replicates. Statistical anal-
ysis was performed by using a two-tailed Student’s t test (for two groups),
whereas analysis of variance (ANOVA) followed byDunnett’s post hoc test
was chosen for use for multiple comparisons. GraphPad InStat (version
5.0) software (GraphPad Software, San Diego, CA) was used for statistical
analysis. Differences were considered statistically significant when P was
0.05 and highly significant when P was0.01 and0.001.
RESULTS
Ply and LytA divert C3b deposition following a cooperative
strategy. The complement system is an efficient immune surveil-
lance systemdetecting foreign intruders and is one of the first lines
of the host immune defense against S. pneumoniae (11). To iden-
tify the role of Ply and LytA in the subversion of pneumococcal
recognition by the key complement component C3b, strains de-
fective in Ply and LytA were constructed. Strains lacking either
LytA or Ply had increased C3b deposition on the bacterial surface
compared to the wild-type strain. Higher levels of C3bwere found
on the lytAmutant than on the ply-defective strain, suggesting that
LytA might avoid recognition by C3b using a Ply-independent
mechanism (Fig. 1A and B). Binding to C3b was even more pro-
nounced for the lytA ply double mutant, indicating that both pro-
teins might act in concert to avoid complement-mediated immu-
nity (Fig. 1A and B). Incubation with human serum depleted of
complement component C1q or factor B (in which CP or AP
activity, respectively, was abolished) confirmed that the presence
of Ply reduced the activation of only the CP, whereas the presence
of LytA inhibited the activation of both complement pathways,
providing additional evidence that LytA impairs complement ac-
tivation independently of Ply (Fig. 1C). A lack of enhanced C3b
deposition when the lytA ply double mutant was incubated in
C1q- or factor B-depleted sera confirmed that the activity of both
cascades was essential for the improved effect in complement eva-
sion mediated by both proteins (Fig. 1).
To exclude the possibility that cellular morphology (i.e., chain
formation) might affect complement interaction, C3b deposition
was analyzed on an isogenic lytBmutant strain, which forms long
chains of bacteria (Fig. 1D and E). There was no increase in com-
plement deposition on the lytB mutant, suggesting that, at least
under our experimental conditions, the increased C3b levels on
the lytA-null strain were not due to differences in cell separation
(Fig. 1). The capsule is known to inhibit complement activity
against the pneumococcus (19), but the content of glucuronic acid
(a component of the CPS of serotype 2) was actually higher for the
lytA mutant strain (0.185 for the wild-type strain versus 0.361 for
the lytAmutant). In addition, the recognition of S. pneumoniae by
antibodies specific to serotype 2 increased in the absence of LytA
(100  17 for the wild-type strain versus 201  121 for the lytA
mutant; P  0. 05). These results suggest that the increased C3b
observed in the lytA-null strain cannot be due to reduced levels of
CPS expression by the lytA mutant.
Ply and LytA prevent activation of the CP on S. pneumoniae.
Activation of the CP by binding of C1q or acute-phase proteins,
such as CRP or serum amyloid P component (SAP), to the bacte-
rium is essential for complement-mediated immunity against S.
pneumoniae, whereas bacterial components impairing activation
are factors critical for immune evasion (6, 10, 37). Hence, we
investigated the effect of deposition ofC1q orCRPon the bacterial
surface using pneumococcal strains lacking Ply, LytA, or both pro-
teins simultaneously. An S. pneumoniae strain defective in either
Ply or LytA showed higher levels of C1q binding, confirming that
both proteins allow S. pneumoniae to impair the activation of the
CP (Fig. 2A and B). This effect was more pronounced in the ab-
sence of LytA, suggesting that this amidase assists with pneumo-
coccal evasion of CP activation using a Ply-independent strategy
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(Fig. 2A and B). CRP deposition was also increased in the absence
of LytA but not in the absence of Ply (Fig. 2C andD). These results
together demonstrated that LytA is more effective than Ply at im-
pairing CP activation. As the increased levels of CRP on the lytA
mutant might be due to differences in the amount of Pcho resi-
dues exposed on the bacterial cell wall, the level of Pcho was mea-
sured using pneumococcal strains of two different serotypes and
the corresponding isogenic lytAmutants. A lack of LytA was asso-
ciated with increased detection of Pcho, indicating that LytA im-
paired the recognition of pneumococci by the CP through effects
on the availability of Pcho for binding to CRP (Fig. 2E to G).
LytA avoids complement immunity by recruiting fluid-
phase downregulators. To prevent damage of host cells by a con-
stant low level of complement activation, a finely controlled set of
soluble andmembrane-bound regulators allows any complement
activation on host cells to be either avoided or strongly inhibited
(11). Trapping of fluid-phase downregulators, such as C4BP and
FH, by certain pathogens is a successful strategy for avoiding the
complement response (13). Binding of the CP inhibitor protein
C4BP was greatly reduced in the lytA-null strain (Fig. 3A and B).
As PspC has recently been reported to be a ligand for C4BP and
FH, an isogenic pspC mutant strain was investigated (15, 17, 18).
The loss of PspC resulted in a reduced proportion of C4BP bind-
ing, with the levels of binding being similar to those found in the
absence of LytA, whereas the loss of both PspC and LytA resulted
in a greater reduction in C4BP binding, demonstrating that both
proteins play a key role in the recruitment of C4BP (Fig. 3A and
B). Fluorescence intensity data also confirmed that a lack of either
LytA or PspC was significantly associated with impaired recruit-
ment of C4BP (23 5 for the wild-type strain, 17 2 for the ply
strain, 8 2 for the lytA strain, 9 1 for the pspC strain, and 6
1 for the pspC lytA strain). To confirm the requirement of LytA for
binding to C4BP, the C4BP binding assays were performed using
a serotype 23F lytA mutant strain (termed S3, the first described
clinical isolate of S. pneumoniae deficient in LytA activity) and the
corresponding lytA transformant (termed S3C) (25) (Fig. 3C
FIG 1 LytA of S. pneumoniae avoids complement activation by a Ply-independent mechanism. (A) C3b deposition on the surface of the wild-type and isogenic
defective strains using NHS, as measured by a flow cytometry assay. (B) Example of a flow cytometry histogram for C3b deposition using NHS. (C) Deposition
of C3b via AP (white bars) or CP (gray bars) activity in human serum in which C1q (white bars) or factor B (gray bars) was depleted, respectively. (D) Binding
toC3b on the surface of thewild-typeD39 strain and the lytB strain. (E) Phase-contrastmicroscopy images of pneumococcal wild-typeD39 and isogenic lytA and
lytB strains. Error bars represent SDs, and asterisks indicate statistically significant differences compared to the results for the wild-type strain: *, P 0.05; **, P
0.01; ***, P 0.001. P was0.01 for the comparison of the C3b results for the lytA ply double mutant versus the single mutants using NHS. For the results for
all defective strains compared to those for the wild type, P was0.001 (one-way ANOVA with Dunnett’s post hoc test). FI, fluorescence intensity.
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and D). The loss of LytA in strain S3 was again associated with
reduced C4BP binding, which was restored by transformation
with the lytA allele (strain S3C), confirming that LytA is a novel
ligand of S. pneumoniae for C4BP (Fig. 3C and D). Direct binding
of purified LytA with different concentrations of purified human
C4BPwas observed, supporting a role for LytA in recruiting C4BP
to the bacterial cell surface (Fig. 3F).
Interaction with FH, the downregulator of the AP, was also
evaluated for the different strains. As expected, a lack of Ply did
not affect FH binding, whereas a loss of LytA or PspC produced
significantly lower levels of FH bound than those found with the
wild-type strain (Fig. 4A and B). In addition, binding of FH to the
pspC lytA double mutant was markedly impaired, indicating that
both proteins are important pneumococcal ligands for FH bind-
FIG 2 Ply and LytA divert classical pathway activation. (A) Deposition of C1q on the surface of the different mutants compared to that on the surface of the
wild-type strain. (B) Example of a flow cytometry histogram for C1q deposition. (C) Recognition of the wild-type strain and the different mutants by CRP. (D)
Example of a flow cytometry histogram for CRP deposition. (E) Pcho levels on the surface of wild-type strains D39 and 1515 of ST2 and ST6B, respectively, and
LytA-deficientmutants. (F) Example of a flow cytometry histogram for the Pcho level on the ST2 strain. (G) Example of a flow cytometry histogram for the Pcho
level on the ST6B strain. Error bars represent SDs, and asterisks indicate a statistically significant difference compared to the results for the wild-type strain: **,
P 0.01; ***, P 0.001. For the results for all defective strains compared to the result for the wild type, Pwas0.001 (one-way ANOVAwith Dunnett’s post hoc
test). CT, control (bacteria incubated in PBS).
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ing (Fig. 4A andB). Fluorescence intensity values confirmed that a
lack of either LytA or PspC on the D39 strain was significantly
associatedwith impaired binding to FH (72 30 for the wild-type
strain, 58 10 for the ply strain, 23 7 for the lytA strain, 5 1
for the pspC strain, and 5  1 for the pspC lytA strain). Recruit-
ment of FH was also evaluated for strains S3 and S3C of serotype
23F (Fig. 4C to E). The proportion of bacteria binding to FH was
similar between both strains (Fig. 4C), but the intensity of the FH
bound was significantly lower in the absence of LytA (Fig. 4D and
E), further supporting a role for LytA in pneumococcal recruit-
ment of high levels of FH. Furthermore, a direct interaction be-
tween purified LytA autolysin and human FH proteins was ob-
served (Fig. 4F). There were no differences in the level of PspC
measured between the wild-type and the lytA-deficient strains
(Fig. 5), confirming that the reduced levels of both C4BP and FH
on the lytA-deficient strain were not caused by the effects of the
lytA mutation on PspC expression (28).
LytA impairs opsonization by degradation of C3b and iC3b.
Proteolytic enzymes can counteract the effects of complement ac-
tivation by bacterial pathogens (13). Hence, the ability of LytA to
cleave the C3b deposited on the bacterial surface and purified
C3b/iC3b components was investigated (Fig. 6). For these exper-
iments, we used a fully active LytA protein (LytA), its C-terminal
domain (C-LytA), and the enzymatically inactive protein
LytAH133A (see above). The degradation of the C3b deposited was
initially investigated by adding the different LytA proteins to a
previously opsonized lytA-deficient strain (Fig. 6A). The results
demonstrated full restoration of the wild-type phenotype only
when the fully active LytA amidase was used (Fig. 6A). This result
was confirmed by Western blotting using an anti-C3 antibody. A
small C3 fragment was observed after addition of the LytA protein
but not after addition of LytAH133A, C-LytA, or the LytC lysozyme
(Fig. 6B). C3b degradation products were also found when LytA
was incubated with either C3b (Fig. 6C) or iC3b (Fig. 6D), con-
firming the direct cleavage of C3b and iC3b components by LytA.
Degradation of the C3b/iC3b deposited on the surface of the non-
encapsulated R6 strain was also observed, indicating that LytA is
involved in C3 degradation independently of capsule expression
(Fig. 6E). These results demonstrated that the pneumococcal LytA
autolysin can cause degradation of the complement components
FIG 3 LytA recruits C4BP to reduce classical pathway activation. (A) Proportion of bacteria positive for C4BP for the D39 wild-type strain and the different
mutants. (B) Example of a flow cytometry histogram for C4BP binding for strains with theD39 genetic background. (C) Proportion of bacteria positive for C4BP
for the S3 lytA mutant strain and the complemented S3C strain (lytA) belonging to ST23F. (D) Example of a flow cytometry histogram for C4BP binding for
the ST23F strains. (E) Direct binding of 10 g/ml of LytA to different concentrations of C4BP by ELISA. Error bars represent SDs, and asterisks indicate a
statistically significant difference between the results for single mutants and the wild-type strain or between the results for different concentrations of C4BP and
those in the absence of protein: **, P 0.01; ***, P 0.001. P was0.05 for the comparison of the C4BP results between the pspC lytA double mutant and the
single mutants.
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C3b and iC3b, partially explaining why the lytA-deficient strain
had higher levels of opsonization with C3b/iC3b.
LytA and Ply divert phagocytosis by professional phago-
cytes. Neutrophils control pneumococcal dissemination by
phagocytosis, a process that requires the opsonization of bacteria
by the complement system (38, 39). Opsonization with HBSS or
heat-killed human serum (HKS) did not support the phagocytosis
of S. pneumoniae by human neutrophils, whereas opsonization
with normal human serum (NHS) did, confirming the impor-
tance of complement-mediated immunity for this process (Fig. 7A
to C). There was increased phagocytosis of the lytA and ply mu-
tants compared to that of the wild-type strain, showing that both
proteins are important bacterial factors involved in evasion of
phagocytosis. The lytAmutant exhibited higher phagocytosis lev-
els than the ply mutant, suggesting that LytA participates in resis-
tance to phagocytosis by a mechanism that is independent of the
release of Ply (Fig. 7A to C). Moreover, synergistic increases in
phagocytosis were found for the lytA ply double mutant in com-
parison to the single mutants and the wild-type strain, demon-
strating that both proteins contribute to evasion of phagocytosis
by neutrophils (Fig. 7A to C).
Adhesion to a murine cell line of AMs was slightly increased in
the absence of Ply or LytA and markedly increased in the double
mutant, suggesting that these two proteins enable S. pneumoniae
to divert the recognition by AMs (Fig. 7D). Time course experi-
mentswere performed to evaluate the phagocytosis processwithin
the macrophage. At an early phase, phagocytosis of the ply and
lytA single mutants was increased (Fig. 7A). Phagocytosis of the
ply lytA double mutant strain was more efficient than that of the
single mutants, confirming the additive effect of the loss of these
FIG 4 LytA binds the downregulator FH to impair the activation of the alternative pathway. (A) Proportion of bacteria positive for FH for the D39 wild-type
strain and the different mutants. (B) Example of a flow cytometry histogram for FH binding for strains with the D39 genetic background. WT, wild type. (C)
Proportion of bacteria positive for FH for the S3 lytA mutant strain and the complemented S3C strain (lytA) belonging to ST23F. (D) Mean fluorescence
intensity (MFI) of FH binding on the surface of the S3 lytA strain and the complemented S3C (lytA) strain. (E) Example of a flow cytometry histogram for FH
binding of the ST23F strains. (F) Direct binding of 10 g/ml of LytA to different concentrations of FH by ELISA. Error bars represent the SDs, and asterisks
indicate statistically significant differences compared to the results for the wild-type strain or between the results for different concentrations of FH compared to
those in the absence of protein: *, P 0.05; **, P 0.01; ***, P 0.001. Pwas0.01 for the comparison of the FH results between the pspC lytA double mutant
and the single mutants.
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two proteins on pneumococcal phagocytosis by AMs (Fig. 7E).
Compared with the bacterial load at 1 h, the bacterial load was
significantly reduced over time, with a more than 100-fold reduc-
tion being found at 4 h, suggesting that once the macrophage has
recognized and phagocytosed pneumococcal strains lacking Ply
and LytA, the machinery of the macrophage efficiently destroys
the engulfed bacteria (Fig. 7F). To confirm this possibility, we
investigatedmaturation of the phagosome containing the lytA ply-
null strain using immunofluorescence microscopy to analyze the
colocalization of phagocytosed GFP-expressing bacteria with
FIG 5 PspC levels are similar in the wild-type and lytA strains. (A) PspC levels on the surface of the D39 wild-type strain and the LytA-deficient mutant. (B)
Example of a flow cytometry histogram for the PspC level. Error bars represent SDs.
FIG 6 LytA degrades C3b and iC3b to impair complement activation. (A) Flow cytometry assay showing degradation of the C3b deposited on a lytA strain that
had previously been opsonized with serum in the presence of 0.3 g of either LytA amidase, the choline-binding domain of LytA (C-LytA), or a mutated LytA
protein without amidase activity (LytAH133A). Error bars represent SDs, and asterisks indicate a statistically significant difference compared to the results for the
wild-type strain: ***, P  0.001. (B) Coomassie-stained polyacrylamide gel showing C3b degradation by FH-factor I (FI) and Western blotting to detect C3
fragments using a lytAmutant opsonized with serum (lanes 1 to 5) and exposed to 3 ng of LytA having amidase activity (lane 2), LytC lysozyme (lane 3), C-LytA
(lane 4), and LytAH133A (lane 5). (C and D) Western blotting to detect fragments of C3b and iC3b degradation, respectively, after exposure of purified C3b (C)
and iC3b (D) to LytA or LytAH133A. (B and D) Arrowheads, typical bands of C3b degradation by FH-FI (65 and 43); arrows, C3b fragments obtained after
digestion with LytA. (E) Degradation of the C3b deposited on the R6 strain in the presence or absence of 0.3 g of LytA.
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FIG 7 Evasion of the phagocytosis process mediated by pneumolysin and LytA. (A) Phagocytosis of the FAM-SE-labeled wild-type strain and the different
mutant strains incubated in 20% normal human serum using a flow cytometry assay. Results are expressed as the fluorescent index (in percent) relative
to the results for the wild-type D39 strain. (B) Example of a flow cytometry histogram for phagocytosis by neutrophils. (C) Opsonophagocytosis of the
different strains expressing GFP by human neutrophils detected by confocal microscopy. DNA was stained by Hoechst, and the actin cytoskeleton was
visualized with rhodamine-phalloidin (Phall-RRX) staining. (D) Attachment to AMs of the different mutant strains compared to that of the wild-type
strain at 1 h postinfection. (E and F) Phagocytosis of the different strains by AMs at 1 h (E) and 4 h (F) postinfection. (G) Phagolysosomal maturation of
AMs during infection with S. pneumoniae lytA ply expressing GFP. DNA was stained with Hoechst, whereas late endosomal markers were visualized using
specific antibodies to recognize LAMP1 (top) and LAMP2 (bottom). Error bars represent the SDs, and asterisks indicate statistically significant differences
compared to the results for the wild-type strain: *, P 0.05; **, P 0.01; ***, P 0.001. P was 0.01 for the comparison of the phagocytosis results for
the lytA ply double mutant and the single mutants for all times except 4 h of phagocytosis by AMs between the lytA ply double mutant and the lytAmutant,
for which P was equal to 0.21. For the results for all defective strains compared to those for the wild type, P was0.001 (one-way ANOVA with Dunnett’s
post hoc test). CT, control (bacteria incubated in PBS).
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early and late endosomal markers. The double mutant was ob-
served in LAMP1- and LAMP2-positive compartments (Fig. 7G),
suggesting that in the absence of Ply and LytA, AMs efficiently
process S. pneumoniae by the conventional phagolysosomal
pathway.
LytA and Ply enhance the establishment of pneumococcal
pneumonia and invasive disease. Mouse models of pneumonia
and sepsis were used to characterize the contribution of Ply and
LytA to the pathogenesis of S. pneumoniae. A lack of either Ply or
LytA was associated with a significant attenuation of virulence in
the sepsis model in comparison to the virulence of the wild-type
strain (Fig. 8). In addition, the virulence of the lytA ply double
mutant was greatly reduced compared to that of the single mu-
tants and the wild-type strain, confirming that both proteins con-
tribute separately to the establishment of pneumococcal sepsis
(Fig. 8A).
In the pneumonia model, the levels of the ply or lytA single
mutants recovered from BAL fluid, lung, and blood samples were
significantly lower than those obtained with the parental strain,
indicating that both proteins are involved in the pathogenesis of
pneumococcal pneumonia (Fig. 8B to D). Moreover, the loss of
both Ply and LytA caused further falls in the number of CFU
recovered from BAL fluid, lung, and blood samples, confirming
that the activity of both proteins is required for the full virulence of
the bacterium in the respiratory tract and for spread from the lung
to the blood (Fig. 8B to D). These results are compatible with the
complement interaction data and confirm that inhibition of com-
plement deposition on S. pneumoniae by the combination of LytA
and Ply is essential for full virulence during systemic infection.
Collectively, these data suggest that the enhanced effect of LytA
and Ply on virulence ismainly due to their combined inhibition of
complement-dependent immunity and phagocytosis.
DISCUSSION
S. pneumoniae is the leading cause of community-acquired pneu-
monia and a major cause of sepsis and meningitis, which are as-
sociated with high morbidity and mortality rates worldwide (2,
40). As one of the most devastating human pathogens, S. pneu-
moniae has developed a wide arsenal of virulence factors to escape
the well-balanced machinery of the immune system (3). Several
proteins are involved in the establishment of IPD, which occurs
when S. pneumoniae invades typically sterile sites, causing bacte-
remic pneumonia and sepsis, or when it crosses the blood-brain
barrier, causing meningitis (3). Ply is a cytolytic protein with a
significant role in pneumonia, sepsis, and meningitis but not, ap-
parently, in carriage (3, 21, 24, 41–43). In contrast, the contribu-
tion of LytA to pneumococcal pathogenesis is poorly understood.
The use of strains deficient in LytA has demonstrated attenuation
of the virulence of these mutants in different models of infection,
suggesting that LytA is important for virulence (39, 44, 45). Acti-
vation of complement-mediated immunity is an essential and
critical component of the host immune response against S. pneu-
moniae (5–7, 9), and Ply has previously been reported to reduce
the CP opsonic activity against S. pneumoniae. The effects of LytA
on virulence have traditionally been linked to the release of Ply
and not to a direct effect of LytA (3, 46, 47). However, our results
demonstrate that LytA plays a critical role in complement evasion
that is independent of the release of Ply. The lytA mutant had
higher levels of CRP, C1q, and C3b binding to its surface than the
plymutant, and the ply lytA double mutant had increased levels of
C3b deposition compared to those for the single mutant strains,
confirming that both proteins confer complement resistance on S.
pneumoniae. Our findings confirm previous data suggesting that
Ply impairs the activation of the CP through C1q (21, 37, 46, 47),
and this might be a possible explanation for the increased recog-
nition by C1q in the absence of both Ply and LytA. Using a lytA
mutant strain, other authors have reported increased sensitivity to
complement-dependent clearance and attributed this attenuation
to its increased bacterial chain length, suggesting that chain length
is an important factor that increases the ability to fix complement
C3b (39). Although a certain deficit in promoting the efficient
separation of daughter cells in the absence of LytA may increase
the level of recognition by C3b, our results suggest that this is
not the full explanation for the increased complement activity
against the lytA mutant, as the formation of longer chains by the
lytB mutant strain does not affect complement deposition (27).
Instead, the lytAmutation affects complement activity by a variety
of mechanisms which lead to increased CP and AP activity.
One mechanism in the lytA mutant was an increased amount
or accessibility to the cell surface of Pcho, the target for CRP,
natural IgM, and SAP binding to S. pneumoniae, and therefore of
innate CP activation.Modification of Pcho levels did not affect the
expression of PspC, another important choline binding protein
involved in complement evasion. Despite this, recruitment of the
fluid-phase downregulators C4BP and FH (both of which are
known to bind to PspC) was decreased in the lytA mutant, and
assays using purified proteins demonstrated direct binding be-
tween LytA or C4BP and FH. Hence, our findings demonstrate
that LytA is an additional pneumococcal protein that reduces
FIG 8 Role of Ply and LytA in the establishment of sepsis (intraperitoneal
inoculation) andpneumococcal pneumonia (intranasal inoculation). (A) Bac-
terial levels recovered from blood at 24 h after pneumococcal sepsis produced
with the wild-type andmutant strains. (B to D) Bacterial levels recovered at 24
h from BAL fluid (B), lung homogenate (C), and blood (D) after pneumonia
caused by the wild-type and defective strains. Error bars represent SDs, and
asterisks indicate statistically significant differences in the levels of the different
mutant bacterial strains compared to the levels of the wild-type strain: *, P
0.05; **, P  0.01; ***, P  0.001. P was 0.05 for the comparison of the
bacterial levels for the lytA ply doublemutant and those for the singlemutants.
For the results for all defective strains compared to the wild type, P was0.01
(one-way ANOVA with Dunnett’s post hoc test).
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complement-mediated immunity by recruiting C4BP and FH. Fi-
nally, we have shown evidence that LytA mediates the direct deg-
radation of C3 by S. pneumoniae, which has previously been de-
scribed (48).
Our data suggest that LytA can inhibit complement activation
against S. pneumoniae by multiple mechanisms. The pneumo-
coccal capsule also alters different aspects of complement- and
phagocyte-mediated immunity, resulting in a profound inhibi-
tion of opsonophagocytosis (19), and effects on the thickness of
the capsule layer could potentially explain the pleiotropic effects
of LytA on complement activity. However, the content of glucu-
ronic acid (a component of the serotype 2 CPS) and the recogni-
tion by specific antibodies to CPS were actually slightly increased
for the lytA mutant. Hence, the effects of LytA on the capsule are
unlikely to explain the increased complement deposition seen on
the lytA mutant; in addition, the direct interactions of purified
LytA with FH, C4BP, and C3 cannot be explained by the effects of
the loss of LytA on other aspects of S. pneumoniae biology. The
location of bound C3b is important because the accessibility of
this component affects the recognition by phagocytic cells. In this
sense, the opsonic activity of C3b deposited on the bacterial cell
wall may be less efficient for induction of phagocytosis. The pres-
ence of antibodies to CPS and the cell wall can also influence
complement deposition (49–51). Human serum contains anti-
bodies to multiple S. pneumoniae antigens, but these would not
affect our results, unless there was amarked difference in the expres-
sion of target antigens between the strains investigated. Instead, our
data indicate that increased complement activity against the lytAmu-
tant was mediated by several separate mechanisms independent of
antibodies, including increased Pcho availability (which could be a
nonphysiological effect of the reduced occupation of choline resi-
dues in the lytA mutant), direct binding of LytA to C4BP and
FH (causing the negative regulation of CP and AP activity,
respectively), and enzymatic activity against C3.
AMs are one of the first barriers of the host immune defense
system against pathogens invading the lungs, and neutrophils are
key players controlling the dissemination of relevant microorgan-
isms through the systemic circulation (52, 53). A loss of Ply and
LytA was associated with the enhanced uptake of S. pneumoniae
by AMs and neutrophils in vitro, confirming that the effects of
these two proteins on complement are important for avoidance
of the recognition and engulfment of S. pneumoniae by phago-
cytic cells. This is in agreement with previous evidence showing
synergistic inhibition of complement-dependent immunity
and phagocytosis for S. pneumoniae proteins (21, 27, 54, 55).
The efficiency of AM phagolysosomal processing and bacterial
killing within the macrophage was increased for the ply and
lytA mutants, demonstrating that a lack of Ply and LytA in-
creases the efficiency of AM clearance of the bacteria through
the phagolysosomal route (56).
Data from the mouse models confirmed that Ply and LytA are
critical proteins that cooperate in the establishment of IPD and
pneumonia. Chain length formation has been identified to be a
factor that might affect bacterial virulence (39). However, pneu-
mococci growing as chains due to a lytB mutation did not show
impaired virulence in our models, suggesting that the attenuation
of the virulence of our lytAmutant was not significantly related to
chain formation (27). The strain with the simultaneous loss of
LytA and Ply showed a marked attenuation in virulence, indicat-
ing that both proteins cooperate in the replication of the bacte-
rium in the respiratory tract and systemic circulation. The im-
paired levels of the mutants in the blood, as previously reported
(21, 41, 43, 47), suggest that pneumococcal strains lacking LytA
and Ply have a reduced ability to breach the epithelial barrier. This
is in agreement with the findings of a previous study showing that a
lack of both LytA and Ply had an additive effect on the median sur-
vival time in amurine sepsismodel of infection (43), and this pheno-
type has previously been shown to be related to complement sensi-
tivity for the ply pspA double mutant (21). Overall, our results
confirmthat LytAplays an important role inbacteremicpneumonia
and sepsis by a mechanism that is independent of Ply release
and is likely to reflect the additive effects seen in vitro of Ply and
LytA on complement inhibition and phagocytosis.
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